guest ::
| Home > Publications database > Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial. > print |
| Home > Publications database > Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial. > print |
| 001 | 305756 | ||
| 005 | 20260202153255.0 | ||
| 024 | 7 | _ | |a 10.1111/ejh.70061 |2 doi |
| 024 | 7 | _ | |a pmid:41216847 |2 pmid |
| 024 | 7 | _ | |a 0902-4441 |2 ISSN |
| 024 | 7 | _ | |a 0036-553X |2 ISSN |
| 024 | 7 | _ | |a 1600-0609 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02376 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Richardson, Tim |0 0009-0006-3588-6376 |b 0 |
| 245 | _ | _ | |a Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial. |
| 260 | _ | _ | |a Oxford |c 2026 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1770042741_1634725 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2026 Mar;116(3):226-234 |
| 520 | _ | _ | |a Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to therapy. Using serum samples of 360 evaluable patients from the prospective GMMG-MM5 trial (EudraCT-No. 2010-019173-16) we assessed the normalization of the kappa/lambda ratio with the Hevylite Assay (HLCr) at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow-up within two years after the end of consolidation. We observed a steady increase in the proportion of patients with normalized HLCr over the course of therapyAchieving HLCr normalization any time until the end of consolidation was associated with a trend towards a prolonged progression-free survival (PFS; hazard ratio (HR) = 0.75, 95% confidence interval (95% CI) = 0.56-1.01, p = 0.06) but not overall survival (OS; HR = 0.94, 95% CI = 0.69-1.26, p = 0.66) in multivariable time-dependent Cox regression analyses. Using a landmark analysis from the end of consolidation there was again a marginally statistically significant effect of HLCr normalization by the end of consolidation on PFS using a multivariable Cox model on the subset of the two study arms with continuous lenalidomide maintenance (HR 0.61, 95% CI 0.37-1.02, p = 0.06). No such effect was observed in study arms in which maintenance was only applied to patients not in CR at the end of consolidation. In conclusion, our analysis of the Hevylite Assay in patients with IgG or IgA myeloma from the GMMG-MM5 study did not find evidence to support the general use of HLCr normalization as a response parameter for predicting PFS or OS. However, the differential effects of HLCr normalization depending on the way in which treatment was adapted to response may be of interest for future study designs on response-adapted therapy. Trial Registration: ISRCTN05622749. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a heavylite assay |2 Other |
| 650 | _ | 7 | |a multiple myeloma |2 Other |
| 650 | _ | 7 | |a prognostic biomarker |2 Other |
| 700 | 1 | _ | |a Mai, Elias |0 0000-0002-6226-1252 |b 1 |
| 700 | 1 | _ | |a Menis, Ekaterina |0 0000-0002-5539-580X |b 2 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 3 |u dkfz |
| 700 | 1 | _ | |a Tichy, Diana |0 P:(DE-He78)2ef631585610340ff425c9c31fcabd03 |b 4 |
| 700 | 1 | _ | |a Miah, Kaya |0 P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf |b 5 |u dkfz |
| 700 | 1 | _ | |a Hänel, Mathias |0 0000-0002-4767-3275 |b 6 |
| 700 | 1 | _ | |a Besemer, Britta |b 7 |
| 700 | 1 | _ | |a Boquoi, Amelie |b 8 |
| 700 | 1 | _ | |a Blau, Igor Wolfgang |b 9 |
| 700 | 1 | _ | |a Michel, Christian S |0 0009-0004-1596-3763 |b 10 |
| 700 | 1 | _ | |a Lindemann, Hans Walter |0 0000-0001-9836-7932 |b 11 |
| 700 | 1 | _ | |a Janjetovic, Snjezana |b 12 |
| 700 | 1 | _ | |a Brossart, Peter |0 0000-0001-5133-1094 |b 13 |
| 700 | 1 | _ | |a Bernhard, Helga |b 14 |
| 700 | 1 | _ | |a Reimer, Peter |b 15 |
| 700 | 1 | _ | |a Salwender, Hans |0 0000-0001-7803-0814 |b 16 |
| 700 | 1 | _ | |a Hose, Dirk |b 17 |
| 700 | 1 | _ | |a Seckinger, Anja |b 18 |
| 700 | 1 | _ | |a Raab, Marc |b 19 |
| 700 | 1 | _ | |a Goldschmidt, Hartmut |b 20 |
| 700 | 1 | _ | |a Scheid, Christof |0 0009-0007-6539-226X |b 21 |
| 700 | 1 | _ | |a Group, German-Speaking Myeloma Multicenter |b 22 |e Collaboration Author |
| 700 | 1 | _ | |a Studien, Koordinierungszentrum Für Klinische |b 23 |e Contributor |
| 700 | 1 | _ | |a Heidelberg, Kks |b 24 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Hämatologie Und |b 25 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Praxisnetzwerk Hämatologie/Internistische |b 26 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis |b 27 |e Contributor |
| 700 | 1 | _ | |a Mergentheim, Caritas Krankenhaus Bad |b 28 |e Contributor |
| 700 | 1 | _ | |a Baden-Baden, Mvz |b 29 |e Contributor |
| 700 | 1 | _ | |a Berlin, Charité Universitätsmedizin |b 30 |e Contributor |
| 700 | 1 | _ | |a Berlin, Charité Universitätsmedizin |b 31 |e Contributor |
| 700 | 1 | _ | |a Berlin-Buch, Helios Klinikum |b 32 |e Contributor |
| 700 | 1 | _ | |a Versorgungszentrum, Medizinisches |b 33 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis |b 34 |e Contributor |
| 700 | 1 | _ | |a Seestrasse, Onkologie |b 35 |e Contributor |
| 700 | 1 | _ | |a Mitte, Klinikum Bielefeld |b 36 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis |b 37 |e Contributor |
| 700 | 1 | _ | |a Bonn, Universitätsklinikum |b 38 |e Contributor |
| 700 | 1 | _ | |a Bonn, Johanniter Krankenhaus |b 39 |e Contributor |
| 700 | 1 | _ | |a Rheinsieg, Onkologie |b 40 |e Contributor |
| 700 | 1 | _ | |a Braunschweig, Städt Klinikum |b 41 |e Contributor |
| 700 | 1 | _ | |a Schwerpunktpraxis, Onkologische |b 42 |e Contributor |
| 700 | 1 | _ | |a Buchholz, Onkologische Praxis Im Krankenhaus |b 43 |e Contributor |
| 700 | 1 | _ | |a Schwerpunktpraxis, Onkologische |b 44 |e Contributor |
| 700 | 1 | _ | |a Chemnitz, Klinikum |b 45 |e Contributor |
| 700 | 1 | _ | |a GmbH, Regiomed Kliniken |b 46 |e Contributor |
| 700 | 1 | _ | |a Cottbus, Carl-Thiem-Klinikum |b 47 |e Contributor |
| 700 | 1 | _ | |a Darmstadt, Klinikum |b 48 |e Contributor |
| 700 | 1 | _ | |a Schwerpunktpraxis, Onkologische |b 49 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Gemeinschaftspraxis Für Hämatologie Und |b 50 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Fachpraxis Für Hämatologie Und |b 51 |e Contributor |
| 700 | 1 | _ | |a Essen, Universitätsklinikum |b 52 |e Contributor |
| 700 | 1 | _ | |a Medizin, Evangelisches Krankenhaus Essen-Werden Zentrum Für Innere |b 53 |e Contributor |
| 700 | 1 | _ | |a Frankfurt, Universitätsklinikum |b 54 |e Contributor |
| 700 | 1 | _ | |a Versorgungszentrum, Agaplesion Medizinisches |b 55 |e Contributor |
| 700 | 1 | _ | |a Frankfurt, Mvz |b 56 |e Contributor |
| 700 | 1 | _ | |a Nordwest, Krankenhaus |b 57 |e Contributor |
| 700 | 1 | _ | |a Facharztzentrum, Interdisziplinäres |b 58 |e Contributor |
| 700 | 1 | _ | |a Frankfurt, Ifs |b 59 |e Contributor |
| 700 | 1 | _ | |a GmbH, Vitanus |b 60 |e Contributor |
| 700 | 1 | _ | |a Rotkreuz-Kliniken, Frankfurter |b 61 |e Contributor |
| 700 | 1 | _ | |a Hämatologie, Pioh-Praxis Für Internistische Onkologie Und |b 62 |e Contributor |
| 700 | 1 | _ | |a Facharztpraxis, Onkologische |b 63 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Für Hämatologie Und |b 64 |e Contributor |
| 700 | 1 | _ | |a Hagen, Kath Krankenhaus |b 65 |e Contributor |
| 700 | 1 | _ | |a Altona, Asklepios Klinik |b 66 |e Contributor |
| 700 | 1 | _ | |a St Georg, Asklepios Klinik |b 67 |e Contributor |
| 700 | 1 | _ | |a Altona, Hämatologisch-Onkologische Praxis |b 68 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Für Hämatologie Und |b 69 |e Contributor |
| 700 | 1 | _ | |a Ug, OncoResearch Lerchenfeld |b 70 |e Contributor |
| 700 | 1 | _ | |a gGmbH, Evangelisches Krankenhaus Hamm |b 71 |e Contributor |
| 700 | 1 | _ | |a Schwerpunktpraxis, Onkologische |b 72 |e Contributor |
| 700 | 1 | _ | |a GmbH, Klinikum Hanau |b 73 |e Contributor |
| 700 | 1 | _ | |a Hannover, Klinikum Region |b 74 |e Contributor |
| 700 | 1 | _ | |a Hannover, Onkologisches Ambulanzzentrum Oaz |b 75 |e Contributor |
| 700 | 1 | _ | |a Heidelberg, Universitätsklinikum |b 76 |e Contributor |
| 700 | 1 | _ | |a Schwerpunktpraxis, Onkologische |b 77 |e Contributor |
| 700 | 1 | _ | |a Heilbronn, Onkologische Schwerpunktpraxis |b 78 |e Contributor |
| 700 | 1 | _ | |a GmbH, Slk Kliniken Heilbronn |b 79 |e Contributor |
| 700 | 1 | _ | |a Tumorerkrankungen, Facharztpraxis Für Hämatologie Und |b 80 |e Contributor |
| 700 | 1 | _ | |a Saarlandes, Universitätsklinikum des |b 81 |e Contributor |
| 700 | 1 | _ | |a Idar-Oberstein, Klinikum |b 82 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Schwerpunktpraxis Für Hämatologie Und |b 83 |e Contributor |
| 700 | 1 | _ | |a Hämatologie, Gemeinschaftspraxis Für |b 84 |e Contributor |
| 700 | 1 | _ | |a Köln, Universitätsklinikum |b 85 |e Contributor |
| 700 | 1 | _ | |a Köln, Onkologie |b 86 |e Contributor |
| 700 | 1 | _ | |a Hämatologie, Praxis Internistischer Onkologie Und |b 87 |e Contributor |
| 700 | 1 | _ | |a Köln, Kliniken |b 88 |e Contributor |
| 700 | 1 | _ | |a Hämatologie, Facharztpraxis Für |b 89 |e Contributor |
| 700 | 1 | _ | |a Lebach, Onkologisches Zentrum |b 90 |e Contributor |
| 700 | 1 | _ | |a Rhein, Klinikum der Stadt Ludwigshafen Am |b 91 |e Contributor |
| 700 | 1 | _ | |a Lüneburg, Onkologische Schwerpunktpraxis |b 92 |e Contributor |
| 700 | 1 | _ | |a der Johannes Gutenberg-Universität Mainz, Universitätsmedizin |b 93 |e Contributor |
| 700 | 1 | _ | |a Facharztzentrum, Med |b 94 |e Contributor |
| 700 | 1 | _ | |a Mannheim, Universitätsmedizin |b 95 |e Contributor |
| 700 | 1 | _ | |a Praxis, Mannheimer Onkologie |b 96 |e Contributor |
| 700 | 1 | _ | |a Medizin, Facharztpraxis Für Innere |b 97 |e Contributor |
| 700 | 1 | _ | |a Medizin, Praxis Für Innere |b 98 |e Contributor |
| 700 | 1 | _ | |a Minden, AöR Johannes Wesling Klinikum |b 99 |e Contributor |
| 700 | 1 | _ | |a Hilf, Kliniken Maria |b 100 |e Contributor |
| 700 | 1 | _ | |a München, Städtisches Klinikum |b 101 |e Contributor |
| 700 | 1 | _ | |a Medizin, Facharztpraxis Für Innere |b 102 |e Contributor |
| 700 | 1 | _ | |a Kliniken, Medius |b 103 |e Contributor |
| 700 | 1 | _ | |a Facharztpraxis, Onkologische |b 104 |e Contributor |
| 700 | 1 | _ | |a Kliniken, Paracelsus |b 105 |e Contributor |
| 700 | 1 | _ | |a Kliniken, Medius |b 106 |e Contributor |
| 700 | 1 | _ | |a Trudbert-Klinikum, Medizinisches Versorgungszentrum Am Siloah St |b 107 |e Contributor |
| 700 | 1 | _ | |a Pinneberg, Onkologische Praxis |b 108 |e Contributor |
| 700 | 1 | _ | |a Medizin/Onkologie, Gemeinschaftspraxis Innere |b 109 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Für |b 110 |e Contributor |
| 700 | 1 | _ | |a Hall, Diakonie-Klinikum Schwäbisch |b 111 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Zaho-Zentrum Für Ambulante Hämatologie Und |b 112 |e Contributor |
| 700 | 1 | _ | |a Jung-Stilling, Diakonie Klinikum |b 113 |e Contributor |
| 700 | 1 | _ | |a Bodensee, Gastroenterologie Onkologie |b 114 |e Contributor |
| 700 | 1 | _ | |a Speyer, Onkologische Schwerpunktpraxis |b 115 |e Contributor |
| 700 | 1 | _ | |a Stuttgart, Marienhospital |b 116 |e Contributor |
| 700 | 1 | _ | |a der Barmherzigen Brüder Trier, Krankenhaus |b 117 |e Contributor |
| 700 | 1 | _ | |a der Borromäerinnen Trier, Klinikum Mutterhaus |b 118 |e Contributor |
| 700 | 1 | _ | |a Trier, Onkologische Schwerpunktpraxis Am Brüderkrankenhaus |b 119 |e Contributor |
| 700 | 1 | _ | |a Rheinsieg, Onkologie |b 120 |e Contributor |
| 700 | 1 | _ | |a Tübingen, Universität |b 121 |e Contributor |
| 700 | 1 | _ | |a GmbH, Omm Optimed Mundial |b 122 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Für |b 123 |e Contributor |
| 700 | 1 | _ | |a Klinik, Ammerland |b 124 |e Contributor |
| 700 | 1 | _ | |a Onkologie, Facharztpraxis Für |b 125 |e Contributor |
| 773 | _ | _ | |a 10.1111/ejh.70061 |g p. ejh.70061 |0 PERI:(DE-600)2027114-1 |n 3 |p 226-234 |t European journal of haematology |v 116 |y 2026 |x 0902-4441 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:305756 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)2ef631585610340ff425c9c31fcabd03 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2024-12-06 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-06 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-06 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J HAEMATOL : 2022 |d 2024-12-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-06 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-06 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-06 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|